“This.config.text.ariaFermé”
AstraZeneca plc’s COVID-19 vaccine (NYSE: AZN) will be produced through Mexico and Argentina for Latin American countries Brazil, according to government officials from both countries, AlJazeera reported on Wednesday.
What happened
Countries will produce between 150 and 250 million initial doses of the COVID-19 vaccine developed through the pharmaceutical corporation in collaboration with researchers at the University of Oxford, according to statements tweeted by President Alberto Fernández of Argentina and The Chancellor of Mexico, Marcelo Ebrard.
The vaccine would be produced in the first part of 2021 and will not generate any benefit in this period, Fernandez revealed. The priority would be to vaccinate the elderly, fitness care professionals and others with pre-existing conditions, Bloomberg reported.
Ebrard said on Twitter that the billionaire founder of America, S.A.B. CV. (NYSE: AMX) Carlos Slim’s basis is to help fund immunization efforts.
Why it’s important
Latin America accounts for the peak of 10 countries seriously affected in the world by COVID-19, Bloomberg said.
The Serum Institute of India Private Limited has also signed an agreement with AstraZeneca to supply one billion doses to low- and middle-income countries.
The Indian company has also signed an agreement with Novavax Inc (NASDAQ: NVAX) for the progression and distribution of its coronavirus vaccine in low- and middle-income countries.
Candidate vaccines from corporations such as Pfizer Inc (NYSE: PFE) and their spouse BioNTech SE (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Johnson and Johnson (NYSE: JNJ) are in or near complex human testing. Phase.
Price action
AstraZeneca’s shares closed with a rise of 2.85% to $56.74 on Wednesday.
Meet Benzinga
Novavax has reached an agreement with the Indian Serum Institute to manufacture the coronavirus vaccine in low- and middle-income countries.
AstraZeneca reports second-quarter results with diversified drug portfolio
GlaxoSmithKline and Sanofi Ink reach agreement with UK to supply up to 60 million doses of COVID-19 vaccine
© 2020 Benzinga.com. Benzinga offers investment advice. All rights are reserved.